TAUG Announces 40% Reduction in Tauri-Gum Production Costs in Support of its Nationwide Launch and Expanded Production
September 17 2020 - 8:13AM
InvestorsHub NewsWire
Enhanced Production
Efficiency Translates into Improved Gross Margins and Additional
Opportunities with Higher Volume Customers
NEW
YORK, NY -- September 17, 2020 -- InvestorsHub NewsWire -- Tauriga
Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a revenue generating, diversified
life sciences company, with a proprietary line of functional
“supplement” chewing gums (Flavors: Pomegranate, Blood Orange,
Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two
ongoing Biotechnology initiatives, today announced that it has
successfully streamlined the Tauri-Gum™ manufacturing process,
driving a material reduction in unitary production costs (nearly
40% over past 16 months). The Company prides itself on
producing a product of outstanding quality while adhering to the
strictest protocols in quality assurance, consumer safety, and
legal and regulatory guidelines.
The
Company has also increased production capacity for its flagship
product line to support its recently announced nationwide launch of
the Tauri-Gum™ brand. In addition, as noted in the Company’s
release dated September 10, 2020, Tauriga’s Rainbow Deluxe Sampler
Pack (“Rainbow Pack”) will officially launch on Sunday, September
20 on the Company’s E-Commerce platform (www.taurigum.com). Pre-Orders for the Rainbow Pack
have been robust, and the Company expects to announce a major
partnership (in the very near term) to enhance both the profile and
scale of this launch.
The
Tauri-Gum™ product line consists of six (6) distinct flavors: three
infused with Cannabidiol (“CBD”) isolate, two infused with
Cannabigerol (“CBG”) isolate, and one infused with Vitamin C &
Zinc.
The
Company’s Tauri-Gum™ product line is: Kosher Certified, Halal
Certified, Vegan Formulated, NON-GMO, Allergen Free, Gluten Free,
Lab Tested, All-Natural Flavors, and 100% Made in the
USA.
ABOUT
TAURIGA SCIENCES INC.
Tauriga
Sciences, Inc. (TAUG) is a revenue generating, diversified life
sciences company, engaged in several major business activities and
initiatives. The company manufactures and distributes several
proprietary retail products and product lines, mainly focused on
the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market
segment. The main product line, branded as Tauri-Gum™,
consists of a proprietary supplement chewing gum that is both
Kosher certified and Vegan formulated (CBD Infused Tauri-Gum™
Flavors: Mint, Blood Orange, Pomegranate) & (CBG Infused
Tauri-Gum™ Flavor: Peach-Lemon). The Company’s
commercialization strategy consists of a broad array of retail
customers, distributors, and a fast-growing E-Commerce business
segment (E-Commerce website: www.taurigum.com). Please visit
our corporate website, for additional information, as well as
inquiries, at www.tauriga.com.
Complementary to the Company’s retail business, are
its two ongoing biotechnology initiatives. The first one
relates to the development of a Pharmaceutical grade version of
Tauri-Gum™, for nausea regulation (specifically designed to help
patients that are subjected to ongoing chemotherapy
treatment). On March 18, 2020, the Company announced that it
filed a provisional U.S. patent application covering its
pharmaceutical grade version of Tauri-Gum™. The Patent, filed
with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS
OF MANUFACTURING, AND METHODS OF TREATMENT”. The second one
relates to a collaboration agreement with Aegea Biotechnologies
Inc. for the co-development of a rapid, multiplexed, Novel
Coronavirus (COVID-19) test with superior sensitivity and
selectivity.
The
Company is headquartered in New York City and operates a regional
office in Barcelona, Spain. In addition, the Company operates
a full time E-Commerce fulfillment center located in LaGrangeville,
New York.
DISCLAIMER -- Forward-Looking
Statements
This
press release contains certain “forward-looking statements” as
defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning
future events. These forward-looking statements are often indicated
by using words such as “may,” “will,” “expects,” “anticipates,”
believes, “hopes,” “believes,” or plans, and may include statements
regarding corporate objectives as well as the attainment of certain
corporate goals and milestones. Forward-looking statements are
based on present circumstances and on management’s present beliefs
with respect to events that have not occurred, that may not occur,
or that may occur with different consequences or timing than those
now assumed or anticipated. Actual results may differ materially
from those expressed in forward looking statements due
to known and unknown risks and uncertainties, such as are not
guarantees of general economic and business conditions, the ability
to successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other filings made from time to time with the Securities and
Exchange Commission. Such forward-looking statements are made only
as of the date of this release, and Tauriga assumes no obligation
to update forward-looking statements to reflect subsequent events
or circumstances. You should not place undue reliance on these
forward-looking statements.
Contact:
CONTACT INFORMATION
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Instagram:
@taurigum
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Public
Relations:
Tiger
Global Management
info@TigerGMP.com